ESC Congress Study Highlights Safety of Aficamten in Hypertrophic Cardiomyopathy

ESC Congress Study Highlights Safety of Aficamten in Hypertrophic Cardiomyopathy At the European Society of Cardiology (ESC) Congress 2024, the cardiology community received its deepest insights yet into the potential of aficamten in the management of hypertrophic cardiomyopathy ahead of the anticipated Q3 submission to the US Food and Drug Administration, including an integrated safety analysis […]

Broadcasting from ESC 2024 – Siddharth Patel, MD, MPH: Abelacimab Could Help Reduce Procedure-Related Bleeding

Broadcasting from ESC 2024 – Siddharth Patel, MD, MPH: Abelacimab Could Help Reduce Procedure-Related Bleeding New data from the AZALEA-TIMI 71 trial is shedding further light on the potential benefits of factor XI inhibition with abelacimab. Presented at the European Society of Cardiology (ESC) Congress 2024, the analysis focused on periprocedural and procedural-related bleeding events, with […]

From the USA: Variable Test Performance Seen With FIT for Advanced Colorectal Neoplasia

From the USA: Variable Test Performance Seen With FIT for Advanced Colorectal Neoplasia Fecal immunochemical tests (FITs) have variable sensitivity and specificity for detecting advanced colorectal neoplasia (ACN), according to a study published online Sept. 3 in the Annals of Internal Medicine. Barcey T. Levy, M.D., Ph.D., from the University of Iowa Carver College of Medicine […]

From ESC 2024 – EMPACT-MI Kidney: SGLT2 Initiation Can Preserve Kidney Function in Post-MI Population

From ESC 2024 – EMPACT-MI Kidney: SGLT2 Initiation Can Preserve Kidney Function in Post-MI Population An analysis of the EMPACT-MI study presented at the European Society of Cardiology (ESC) Congress 2024 underlines the safety of initiating SGLT2 inhibitor therapy in patients with a history of acute myocardial infarction. The analysis demonstrates use of the SGLT2 inhibitor empagliflozin […]

Reporting from ESC 2024 – PALISADE: Plozasiran Offers Hope for Treating Familial Chylomicronemia Syndrome

Reporting from ESC 2024 – PALISADE: Plozasiran Offers Hope for Treating Familial Chylomicronemia Syndrome New phase 3 data from plozasiran, a small interfering RNA therapy, presented at the European Society of Cardiology (ESC) Congress 2024 indicates there could be hope on the horizon for patients with familial chylomicronemia syndrome (FCS). The trial, named the PALISADE trial, found […]

Directly from ESC 2024 – Kausik Ray, MD, MPhil: INTERASPIRE and the Expanding Knowledge Base for Lipoprotein(a)

Directly from ESC 2024 – Kausik Ray, MD, MPhil: INTERASPIRE and the Expanding Knowledge Base for Lipoprotein(a) Few topics or biomarkers have garnered the same amount of attention for their association with cardiovascular risk in recent years as lipoprotein(a) [Lp(a)]. This trend continued at the European Society of Cardiology (ESC) Congress 2024, as the cardiology community and […]

Long-Term Data from ESC 2024 Reinforces Safety, Efficacy Profile of Mavacamten in oHCM

Long-Term Data from ESC 2024 Reinforces Safety, Efficacy Profile of Mavacamten in oHCM New long-term data are highlighting the sustained benefits of mavacamten (Camzyos) among patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM). Presented during the European Society of Cardiology (ESC) Congress 2024 and simultaneously published in the European Heart Journal, the latest data release from the MAVA-LTE trial offers […]

Directly from ESC 2024 – OCEANIC-AF: Asundexian Patients Have Nearly 4x Stroke, Embolism Risk vs Apixaban Patients

Directly from ESC 2024 – OCEANIC-AF: Asundexian Patients Have Nearly 4x Stroke, Embolism Risk vs Apixaban Patients The OCEANIC-AF trial has missed its primary endpoint, with use of asundexian nearly quadrupling the risk of stroke or systemic embolism compared with apixaban among high-risk patients with atrial fibrillation. Presented at the European Society of Cardiology (ESC) Congress 2024, […]